| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT00228891 Details | 2016-08-10 Interventional | 2/3 | 152 | Insulin Insulin, Globin… Diabetes Mellit… Diabetic Neurop… Diabetes Mellit… | Administrative - | |||
| NCT00228878 Details | 2016-08-10 Interventional | 2/3 | 152 | Insulin Insulin Aspart Diabetes Mellit… | Administrative - | |||
| NCT00228865 Details | 2016-08-10 Interventional | 2/3 | 75 | Insulin Insulin, Globin… Insulin, Isopha… Diabetes Mellit… | Administrative - | |||
| NCT00361907 Details | 2016-08-09 Interventional | 2/3 | 105 | Insulin Insulin, Globin… Diabetes Mellit… | Administrative - Suspended by IRB - | |||
| NCT00538538 Details | 2016-08-08 Interventional | 1 | 0 | Ranibizumab Hemorrhage Macular Degener… Retinal Hemorrh… | This condition can now be managed in the office with an injection of Lucentis. - | |||
| NCT00112723 Details | 2016-08-08 Interventional | 1/2 | 46 | Alvocidib Hodgkin Disease Immunoblastic L… Leukemia, Lymph… Leukemia, T-Cel… Leukemia-Lympho… Lymphoma Lymphoma, B-Cel… Lymphoma, B-Cel… Lymphoma, Folli… Lymphoma, Large… Lymphoma, Large… Lymphoma, Mantl… Lymphoma, Non-H… Lymphoma, T-Cel… Lymphoma, T-Cel… Lymphomatoid Gr… Multiple Myelom… Mycoses Mycosis Fungoid… Neoplasms, Plas… Recurrence Sezary Syndrome Waldenstrom Mac… Adult Lymphocyt… Adult Lymphocyt… Adult Mixed Cel… Adult Nodular S… Anaplastic Larg… Angioimmunoblas… Extranodal Marg… Nodal Marginal … Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Adult… Recurrent Cutan… Recurrent Grade… Recurrent Grade… Recurrent Grade… Recurrent Mantl… Recurrent Margi… Recurrent Mycos… Recurrent Small… Refractory Mult… Splenic Margina… Stage I Multipl… Stage II Multip… Stage III Multi… Waldenström Ma… | Administratively Complete - | |||
| NCT01528137 Details | 2016-08-02 Interventional | 1 | 4 | Lactoferrin Talactoferrin a… Carcinoma Carcinoma, Non-… Carcinoma, Squa… Carcinoma, Verr… Head and Neck N… Laryngeal Disea… Laryngeal Neopl… Lung Neoplasms Nasopharyngeal … Neoplasms, Unkn… Oropharyngeal N… Paranasal Sinus… Recurrence Salivary Gland … Squamous Cell C… Tongue Neoplasm… Metastatic Squa… Recurrent Metas… Recurrent Saliv… Recurrent Squam… Recurrent Squam… Recurrent Squam… Recurrent Squam… Recurrent Squam… Recurrent Squam… Recurrent Verru… Recurrent Verru… Salivary Gland … Stage III Saliv… Stage III Squam… Stage III Squam… Stage III Squam… Stage III Squam… Stage III Squam… Stage III Squam… Stage III Verru… Stage III Verru… Stage IV Non-sm… Stage IV Squamo… Stage IV Squamo… Stage IVA Saliv… Stage IVA Squam… Stage IVA Squam… Stage IVA Squam… Stage IVA Squam… Stage IVA Verru… Stage IVA Verru… Stage IVB Saliv… Stage IVB Squam… Stage IVB Squam… Stage IVB Squam… Stage IVB Squam… Stage IVB Verru… Stage IVB Verru… Stage IVC Saliv… Stage IVC Squam… Stage IVC Squam… Stage IVC Squam… Stage IVC Squam… Stage IVC Verru… Stage IVC Verru… Tongue Cancer | Negative data from another trial led to termination of this trial by sponsor. - | |||
| NCT02758067 2015-001749-97 Details | 2016-08-01 Interventional | 3 | 0 | Brexpiprazole Risperidone Schizophrenia | This study was withdrawn for administrative reasons. There were no safety concerns. - | |||
| NCT01615939 Details | 2016-08-01 Interventional | 4 | 17 | Bupivacaine Ropivacaine Fracture of Foo… | The study has been terminiated due to minimal subject recruitment Early termination leading to small numbers of subjects analyzed | |||
| NCT01500772 2011-004653-31 Details | 2016-08-01 Interventional | 3 | 6 | Peginterferon a… Ribavirin Hepatitis Hepatitis A Hepatitis C Hepatitis C, Ch… | - Due to early termination of the study, none of the planned outcome measures could be evaluated. | |||
| NCT01790854 Details | 2016-07-29 Interventional | 4 | 195 | Prasugrel Hydro… Acute Coronary … Adverse Reactio… | Low events rate. Scarce economical resources - | |||
| NCT00471809 Details | 2016-07-29 Interventional | 4 | [1 Refs] | - | Azithromycin Budesonide Montelukast Salmeterol Xina… Asthma | The CARE Network DSMB recommended to the NHLBI that the MARS trial be terminated, based on a
futility analysis with 55 randomized children. - | ||
| NCT01605162 Details | 2016-07-28 Interventional | 2 | 8 | 10-((4-hydroxyp… Melanoma Unresectable St… Wild Type BRAF … | - - | |||
| NCT01555073 Details | 2016-07-28 Interventional | 4 | 23 | Celecoxib Pregabalin Leiomyoma Uterine Artery … Uterine Fibroid… | Subjects did not meet inclusion criteria Early termination due to lost of follow-up for primary outcome at 3 months | |||
| NCT02673866 Details | 2016-07-27 Interventional | 2 | 0 | DS-1971a Pregabalin Diabetic Neurop… Neuralgia Diabetes Neuropathic Pai… | reassessment of phase 2 study indication - | |||
| NCT01053663 Details | 2016-07-27 Interventional | 1 | 9 | Oseltamivir Influenza, Huma… Influenza | The study was terminated prematurely after three influenza seasons. Low number of participants enrolled in the study at the time that the study was terminated limits conclusions that can be derived from the study data. | |||
| NCT02640833 2015-003302-16 Details | 2016-07-26 Interventional | 1 | 0 | Venetoclax Leukemia Leukemia, Lymph… Leukemia, Lymph… Lymphoma Lymphoma, Non-H… Chronic Lymphoc… Non-Hodgkin Lym… Small Lymphocyt… | Study Stopped - | |||
| NCT02627430 Details | 2016-07-26 Interventional | 1 | 0 | Talazoparib Adenocarcinoma Breast Neoplasm… Carcinoma Cystadenocarcin… Neoplasms Neoplasms, Cyst… Recurrence Triple Negative… Adult Solid Neo… Estrogen Recept… Fallopian Tube … HER2/Neu Negati… Ovarian Serous … Ovarian Serous … Primary Periton… Progesterone Re… Recurrent Breas… Recurrent Fallo… Recurrent Ovari… Recurrent Prima… Triple-Negative… | Other - Protocol moved to Withdrawn - | |||
| NCT02317419 2014-002935-32 Details | 2016-07-26 Interventional | 1 | 15 | Gemcitabine LMB-100 Paclitaxel Cancer | The study was prematurely terminated because the emerging benefit:risk ratio did not justify
continuing dosing patients. - | |||
| NCT02099695 Details | 2016-07-26 Interventional | 3 | 0 | Oxybutynin Hyperhidrosis | The company changed the strategy. - |